Table 2.
All adverse events observed in the 22 interferon-α 2b-treated patients with melanoma
| Grade, n (%) | ||||
|---|---|---|---|---|
| Adverse events* | I | II | III | IV |
| Hematologic | ||||
| Neutropenia | 7 (31) | 5 (23) | 3 (14) | 0 |
| Lymphocytopenia | 10 (45) | 5 (23) | 2 (9) | 0 |
| Liver function | ||||
| AST | 15 (68) | 13 (59) | 10 (45) | 0 |
| ALT | 20 (91) | 15 (68) | 12 (54) | 0 |
| Nonhematologic | ||||
| Fatigue | 17 (77) | 6 (27) | 2 (9) | 0 |
| Nausea | 8 (36) | 7 (32) | 2 (9) | 0 |
| Vomiting | 5 (22) | 4 (18) | 2 (9) | 0 |
| Anorexia | 9 (40) | 3 (14) | 0 | 0 |
| Diarrhea | 3 (14) | 0 | 0 | 0 |
| Flu-like syndrome† | 17 (77) | 7 (31) | 0 | 0 |
| Autoimmunity | 0 | 0 | 0 | 0 |
AST, aspartate transaminase; ALT, alanine transaminase.
*Assessed using the National Cancer Institute-Common Terminology Criteria for Adverse Events version 3.0.
†Flu-like syndrome includes headache, fever, myalgia, and chills.